<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="7051"><DrugName>ISIS-5876</DrugName><DrugSynonyms><Name><Value>ISIS-5876</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VCAM-1 antisense, Isis</Value></Name><Name><Value>PECAM-1 antisense, Isis</Value></Name></DrugSynonyms><CompanyOriginator id="17269">Ionis Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="17269">Ionis Pharmaceuticals Inc</Company><Company id="22546">Boehringer Ingelheim GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17269" type="Company"><TargetEntity id="4295906873" type="organizationId">Ionis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="22546" type="Company"><TargetEntity id="4295869234" type="organizationId">Boehringer Ingelheim GmbH</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="5400" type="Action"><TargetEntity id="844" type="Mechanism">VCAM-1 Antagonists</TargetEntity><TargetEntity id="2614" type="Mechanism">Anti-CD106 (VCAM-1)</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01936" type="ciTarget"><TargetEntity id="14883660674123" type="siTarget">Vascular cell adhesion protein 1</TargetEntity><TargetEntity id="2665" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="5400">Vascular cell adhesion protein 1 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="7294">Antisense oligonucleotide inhibitor</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="569">Oligonucleotide antisense</Technology></Technologies><LastModificationDate>2008-10-15T12:08:06.000Z</LastModificationDate><ChangeDateLast>2014-04-09T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Isis Pharmaceuticals, in collaboration with &lt;ulink linkType="Company" linkID="22546"&gt;Boehringer Ingelheim&lt;/ulink&gt;, was investigating &lt;ulink linkType="Drug" linkID="7051"&gt;ISIS-5876&lt;/ulink&gt;, an antisense oligonucleotide specific for VCAM-1, for the potential treatment of  inflammatory diseases [&lt;ulink linkType="reference" linkID="156479"&gt;156479&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="191670"&gt;191670&lt;/ulink&gt;]; however, no further development has been reported by either company since 1998 [&lt;ulink linkType="reference" linkID="343460"&gt;343460&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="7051"&gt;ISIS-5876&lt;/ulink&gt; was shown to reduce the IL-1beta-induced human intestinal microvascular endothelial cell binding of U937 cells [&lt;ulink linkType="reference" linkID="326452"&gt;326452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company had also designed similar antisense oligonucleotides for platelet cell adhesion molecule 1 (PECAM-1) [&lt;ulink linkType="reference" linkID="343460"&gt;343460&lt;/ulink&gt;]; these are claimed in patent WO-09947708.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22546">Boehringer Ingelheim GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-09-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-09-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22546">Boehringer Ingelheim GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-07-31T00:00:00.000Z</StatusDate><Source id="181267" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1993-09-30T00:00:00.000Z</StatusDate><Source id="156479" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01936"><Name>Vascular cell adhesion protein 1</Name><SwissprotNumbers><Swissprot>P19320</Swissprot><Swissprot>P29533</Swissprot><Swissprot>P29534</Swissprot><Swissprot>Q28260</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17269">Ionis Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116818" title="Isis Pharmaceuticals and Boehringer Ingelheim to research and develop cell adhesion programs"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>